Skip to main content
18 November 2026

Seawolf Therapeutics Raises $100M to Accelerate Genetic Medicine Innovation

Seawolf Therapeutics announced its emergence from stealth, having raised $100 million to transform patient outcomes through the use of its proprietary DNA delivery platform.

Founding investor Versant Ventures led the seed round, followed by the Series A financing with Versant, MPM BioImpact, and Novartis Venture Fund (NVF), and participation from Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments, Pathway to Cures (the philanthropic venture arm of the National Bleeding Disorders Foundation), and others.

“Seawolf is charting a new course in patient care through LNP-based DNA medicines,” said Elizabeth Alcamo, Ph.D., president and CEO. “With a strong syndicate of investors and our collaboration with Sanofi, we are well-positioned to execute on our next stage of growth, which will include advancing our lead program for metabolic diseases and collaborating with Sanofi in its mission to develop therapies for patient unmet needs.”

slot gacor